u/RoseW2025

NASA made one thing crystal clear yesterday:
It’s no longer just about landing on the Moon.It’s about building a lunar economy.

They emphasized High-volume production**，Lunar infrastructure，Moon Base，**Persistent operations and Commercial ecosystem

That is a MASSIVE shift.

Now NASA, DoD, ESA, and commercial customers are all investing in these long-term themes.

RDW is positioned across Space infrastructure**，In-space manufacturing，Advanced solar arrays，Robotics & autonomous systems，Space biotech，**Defense & national security.

RDW will fly while the foundation of the space economy is being built and US+NATO+ other countries defense budget are expanding.

I believe more contracts are coming for RDW.

The next several months could be an important period for IBRX.

Here are some of the catalysts investors are watching:

• Potential Russell 1000 inclusion, which could increase institutional and passive ownership.
• Continued Anktiva commercial rollout.
• January 2027 PDUFA for the papillary-only NMIBC indication, with the possibility of an earlier FDA decision.
• Improving BCG supply.
• International expansion across Europe, the UK and Macau.
• Additional oncology data and company updates. Dr. Patrick Soon-Shiong recently said on the Sean Spicer Show that ImmunityBio expects to provide additional company updates in July.
· AI-powered manufacturing platform and next-generation NK cell technology have great potential to change the world.

An estimated 15,000–20,000 cancer patients are still waiting for access to Anktiva.

Continued progress in regulatory approvals and supply expansion could benefit both patients and the company's long-term growth.

Current published data show short interest at approximately 33.5% of the float, with about 9-14 days to cover.

The next few months should be an interesting period for IBRX.

We may see a huge short squeeze. Good luck to all!

The next several months could be an important period for IBRX.

Here are some of the catalysts investors are watching:

• Potential Russell 1000 inclusion, which could increase institutional and passive ownership.
• Continued Anktiva commercial rollout.
• January 2027 PDUFA for the papillary-only NMIBC indication, with the possibility of an earlier FDA decision.
• Improving BCG supply.
• International expansion across Europe, the UK and Macau.
• Additional oncology data and company updates. Dr. Patrick Soon-Shiong recently said on the Sean Spicer Show that ImmunityBio expects to provide additional company updates in July.
· AI-powered manufacturing platform and next-generation NK cell technology have great potential to change the world.

An estimated 15,000–20,000 cancer patients are still waiting for access to Anktiva.

Continued progress in regulatory approvals and supply expansion could benefit both patients and the company's long-term growth.

Current published data show short interest at approximately 33.5% of the float, with about 9-14 days to cover.

The next few months should be an interesting period for IBRX.

We may see a huge short squeeze. Good luck to all!

The next several months could be an important period for IBRX.

Here are some of the catalysts investors are watching:

• Potential Russell 1000 inclusion, which could increase institutional and passive ownership.
• Continued Anktiva commercial rollout.
• January 2027 PDUFA for the papillary-only NMIBC indication, with the possibility of an earlier FDA decision.
• Improving BCG supply.
• International expansion across Europe, the UK and Macau.
• Additional oncology data and company updates. Dr. Patrick Soon-Shiong recently said on the Sean Spicer Show that ImmunityBio expects to provide additional company updates in July.
· AI-powered manufacturing platform and next-generation NK cell technology have great potential to change the world.

An estimated 15,000–20,000 bladder cancer patients are still waiting for access to Anktiva.
Continued progress in regulatory approvals and supply expansion could benefit both patients and the company's long-term growth.

Current published data show short interest at approximately 33.5% of the float, with about 9-14 days to cover.

The next few months should be an interesting period for IBRX.

We may see a huge short squeeze. Good luck to all!

A lot of investors still view Redwire mainly as a speculative “space stock,” but the business increasingly looks more like a space-defense infrastructure supplier.

Its exposure spans:
• satellite systems
• sensors
• solar arrays
• space manufacturing
• autonomous systems
• defense drone technology
• mission-critical aerospace infrastructure

What caught my attention recently was the acceleration in backlog.
RDW reported approximately $498M contracted backlog, up more than 70% YoY, with a 1.92 book-to-bill ratio.

To me, that suggests demand is scaling faster than revenue recognition.

Another interesting point:
Large defense/government customers usually do not commit to long-duration mission-critical programs unless they have significant confidence in execution capability and strategic relevance.

What I find particularly interesting is the valuation gap inside the sector.

Some space names are trading at extremely elevated sales multiples.
For example, RKLB’s price-to-sales ratio has recently ranged roughly between ~70x and 130x depending on the source and market move.

Meanwhile RDW has often traded closer to ~4–9x sales despite:
• accelerating backlog growth
• expanding defense exposure
• increasing strategic relevance
• growing autonomous systems capability

The leadership team is also unusually deep for a company of this size:
• former NASA leadership
• former Raytheon/Booz executives
• former senior national security officials
• former Army Chief of Staff
• Edge Autonomy leadership

Not saying RDW is risk-free.
Execution risk and integration risk obviously exist.

But from a risk/reward perspective, RDW looks increasingly interesting to me as a potentially underappreciated infrastructure play within the broader space-defense ecosystem.

Redwire is the picks-and-shovels infrastructure company behind the space and defense economy.

Its business spans:

• Satellites
• Sensors
• Solar arrays
• Space manufacturing
• Autonomous systems
• Defense drone technology
• Mission-critical aerospace infrastructure

While others focus mainly on launches, RDW is building the tools and systems the entire ecosystem depends on.

The company already has a massive and rapidly growing backlog. RDW recently reported a record contracted backlog of approximately $498 million, up more than 70% YoY, with a strong 1.92 book-to-bill ratio — showing demand is accelerating even faster than revenue recognition.

Another bullish signal:Large defense and government customers typically do not award long-duration mission-critical contracts unless they have strong confidence in a company’s technology, execution capability, and long-term strategic importance.

And yet the valuation still looks deeply undervalued relative to many high-flying space names.

Some space companies are trading at extremely rich valuations.

RKLB’s price-to-sales ratio has recently ranged roughly between 70x and well above 100x sales depending on the source and market move.

Meanwhile, RDW has often traded closer to only ~4–9x sales despite accelerating growth, expanding defense exposure, huge backlog, and increasing strategic importance.

At these valuation levels, it would not be surprising if institutional accumulation is already quietly taking place while retail investors remain focused on higher-profile momentum names.

What also separates RDW is the leadership team.

This is a serious defense-space-industrial network:

• CEO Peter Cannito — former executive connected to Raytheon, Booz Allen Hamilton, EOIR Technologies, and former U.S. Marine Corps officer.
• Mike Gold — former NASA Associate Administrator and key architect of the Artemis Accords.
• Frank Calvelli — former Assistant Secretary of the Air Force for Space Acquisition & Integration and former senior leader at the National Reconnaissance Office (NRO).
• Gen. James McConville — former Chief of Staff of the U.S. Army.
• Steve Adlich — former CEO of Edge Autonomy, one of the most respected autonomous drone companies in defense technology. That is a deep U.S. defense and aerospace network.

Additional bullish signals continue building:

• accelerating defense spending globally
• SpaceX-driven infrastructure expansion
• sovereign space race dynamics
• increasing autonomous warfare demand
• growing U.S. national security focus on resilient space infrastructure##The market eventually rerates strategic infrastructure companies.

RDW still looks like one of the most undervalued names in the entire space-defense sector.

Shorts betting against strategic infrastructure companies with accelerating backlog growth and expanding defense exposure may eventually find themselves badly trapped.

Buy and hold.Patience is where the big money is made.

Management would not voluntarily walk into these closed-door sessions—where sophisticated investors can grill them directly on the papillary sBLA filing decision (expected ~May 8–10), Anktiva commercial traction, Dunkirk manufacturing scale-up, and cash runway—unless they were extremely comfortable with the outcome. The timing overlaps perfectly with the anticipated positive FDA filing acceptance and the May 8 Q1 earnings call, which together form a near-term catalyst cluster.
This is not the behavior of a company bracing for bad news; it is the behavior of a leadership team that believes the upcoming data and regulatory milestones will validate the long-term story. For shareholders, it reinforces the case to hold and potentially add on any weakness, knowing that strong institutional feedback from the bus tour can accelerate momentum. For the 37–45% of the float currently short, this setup is increasingly uncomfortable: any positive tone or sBLA acceptance news risks a rapid short squeeze, especially with the stock already showing resilience near $7.
In short, the company’s willingness to engage directly with the Street right now is one of the strongest bullish tells we’ve seen in months.​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​

Management would not voluntarily walk into these closed-door sessions—where sophisticated investors can grill them directly on the papillary sBLA filing decision (expected ~May 8–10), Anktiva commercial traction, Dunkirk manufacturing scale-up, and cash runway—unless they were extremely comfortable with the outcome. The timing overlaps perfectly with the anticipated positive FDA filing acceptance and the May 8 Q1 earnings call, which together form a near-term catalyst cluster.
This is not the behavior of a company bracing for bad news; it is the behavior of a leadership team that believes the upcoming data and regulatory milestones will validate the long-term story. For shareholders, it reinforces the case to hold and potentially add on any weakness, knowing that strong institutional feedback from the bus tour can accelerate momentum. For the 37–45% of the float currently short, this setup is increasingly uncomfortable: any positive tone or sBLA acceptance news risks a rapid short squeeze, especially with the stock already showing resilience near $7.
In short, the company’s willingness to engage directly with the Street right now is one of the strongest bullish tells we’ve seen in months.​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​